欢迎访问《中国临床药理学与治疗学》杂志官方网站,今天是 分享到:

中国临床药理学与治疗学 ›› 2023, Vol. 28 ›› Issue (2): 178-183.doi: 10.12092/j.issn.1009-2501.2023.02.008

• 药物治疗学 • 上一篇    下一篇

右旋糖酐铁片对合并铁缺乏的射血分数减低的心力衰竭患者的影响

彭勇,范剑峰,熊旭华,肖冬平,高招波,郑春华   

  1. 南昌大学第三附属医院心内二科,南昌 330006,江西
  • 收稿日期:2022-11-07 修回日期:2023-02-21 出版日期:2023-02-26 发布日期:2023-03-10
  • 通讯作者: 郑春华,男,博士研究生,主任医师,教授,硕士研究生导师,研究方向:介入心脏病学、心脏起搏与电生理。 E-mail: zch6595@163.com
  • 作者简介:彭勇,男,硕士研究生,主治医师,研究方向:心力衰竭、心脏起搏与电生理。 E-mail: yongpengnc@qq.com
  • 基金资助:
    江西省卫生健康委科技计划项目资助(20204006)

Effect of iron dextran dispersible tablets on heart failure patients with iron deficiency

PENG Yong, FAN Jianfeng, XIONG Xuhua, XIAO Dongping, GAO Zhaobo, ZHENG Chunhua   

  1. The Second Department of Cardiology, The Third Affiliated Hospital of Nanchang University, Nanchang 330006, Jiangxi, China
  • Received:2022-11-07 Revised:2023-02-21 Online:2023-02-26 Published:2023-03-10

摘要:

目的:探讨右旋糖酐铁分散片对合并铁缺乏的射血分数减低的心力衰竭患者的疗效。方法:选取2020年1月至2022年6月南昌大学第三附属医院心内科收治的45例合并铁缺乏的射血分数减低的心力衰竭患者作为研究对象,按随机数字表法将其分为对照组和观察组,对照组给予沙库巴曲缬沙坦钠片等常规抗心力衰竭治疗,观察组在对照组抗心力衰竭治疗基础上给予日3次口服右旋糖酐铁片每次50 mg,连续8周。比较两组患者用药后(24周)的6 min步行距离,血红蛋白、血清铁蛋白、N末端B型利钠肽前体、左室射血分数、左室舒张末内径及堪萨斯城心肌病问卷评分情况。结果:治疗前,两组患者6 min步行距离、血红蛋白、血清铁蛋白、N末端B型利钠肽前体、左室射血分数、左室舒张末内径、临床综合评分和总体评分比较,差异无统计学意义(P>0.05);治疗后,观察组患者6 min步行距离长于治疗前及对照组,观察组患者血清铁蛋白水平高于对照组,两组患者N末端B型利钠肽前体水平低于治疗前,左室舒张末内径短于治疗前,左室射血分数、临床综合评分和总体评分均高于治疗前,且观察组患者左室舒张末内径短于对照组,堪萨斯城心肌病问卷评分临床综合评分和总体评分均高于对照组,差异有统计学意义(P<0.05)。两组患者不良反应总发生率比较,差异无统计学意义(P>0.05)。结论:右旋糖酐铁片应用于合并铁缺乏的射血分数减低的心力衰竭患者,可提高其运动耐力和生活质量。

关键词: 右旋糖酐铁, 铁缺乏, 射血分数减低, 心力衰竭

Abstract:

AIM: To evaluate the clinical effect of Iron Dextran Dispersible Tablets on patients with chronic heart failure who reduced ejection fraction after 24 weeks. METHODS: From January 2020 to June 2022, forty-five patients with heart failure complicated with iron deficiency and reduced ejection fraction were selected as the research objects. According to the random number table, they were randomly divided into control group and observation group.The control group was given routine anti-heart failure treatment such as Sacubitril Valsartan sodium tablets, while the observation group was given iron dextran dispersible tablets 50 mg three times a day on the basis of the anti-heart failure treatment of the control group for 8 weeks. The 6-minute walking distance, Hemoglobin, Serum Ferritin, N-terminal B-type natriuretic peptide precursor, Left Ventricular Ejection Fraction, Left Ventricular end Diastolic Diameter and 12-item Kansas City Cardiomyopathy Questionnaire (KCCQ-12) overall summary score and clinical summary score were compared between the two groups.RESULTS: There was no significant difference in baseline data between the two groups (P>0.05). After treatment, the 6-minute walking distance in the observation group was longer than that in the control group, while the serum ferritin level in the observation group was higher than that in the control group. The N-terminal pro-B-type natriuretic peptide level in the two groups was lower than that before treatment, and the left ventricular end diastolic diameter was shorter than that before treatment, and the left ventricular ejection fraction, clinical comprehensive score and symptom score were higher than that before treatment. The difference was statistically significant (P<0.05). There was no significant difference in the total incidence of adverse reactions between the two groups (P>0.05). CONCLUSION: Iron Dextran Dispersible Tablets can improve the exercise endurance and quality of life of patients with chronic heart failure who reduced ejection fraction after 24 weeks.

Key words: iron dextran dispersible tablets, iron deficiency, reduced ejection fraction, heart failure

中图分类号: